Armata Pharmaceuticals, Inc. financial data

Symbol
ARMP on NYSE
Location
5005 Mcconnell Ave, Los Angeles, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 12, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11.7 % -62.4%
Debt-to-equity -229 % +30.4%
Return On Equity 70.3 % -21.1%
Return On Assets -54.5 % -40.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.3M shares +0.41%
Common Stock, Shares, Outstanding 3.62M shares -90%
Entity Public Float 30.3M USD +142%
Common Stock, Value, Issued 362K USD 0%
Weighted Average Number of Shares Outstanding, Basic 36.2M shares +0.13%
Weighted Average Number of Shares Outstanding, Diluted 36.2M shares +0.13%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12.3M USD -5.62%
Operating Income (Loss) -33.3M USD +19.6%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -46.9M USD -13.4%
Earnings Per Share, Basic -1 USD/shares -14%
Earnings Per Share, Diluted -1 USD/shares +24.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 14.8M USD -13.9%
Other Assets, Current 759K USD -65.8%
Assets, Current 16.9M USD -24.4%
Property, Plant and Equipment, Net 12.6M USD -7.76%
Operating Lease, Right-of-Use Asset 39.9M USD -5.52%
Intangible Assets, Net (Excluding Goodwill) 10.3M USD 0%
Goodwill 3.49M USD 0%
Other Assets, Noncurrent 973K USD +28.9%
Assets 89.5M USD -8.88%
Accounts Payable, Current 1.28M USD -29.5%
Liabilities, Current 140M USD +18.4%
Deferred Income Tax Liabilities, Net 3.08M USD 0%
Operating Lease, Liability, Noncurrent 26.8M USD -3.91%
Liabilities 185M USD +24.1%
Retained Earnings (Accumulated Deficit) -377M USD -14.2%
Stockholders' Equity Attributable to Parent -95.6M USD -87.5%
Liabilities and Equity 89.5M USD -8.88%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.58M USD +28.4%
Net Cash Provided by (Used in) Financing Activities 9.99M USD -71.4%
Net Cash Provided by (Used in) Investing Activities -99K USD +60.4%
Common Stock, Shares Authorized 217M shares 0%
Common Stock, Shares, Issued 36.2M shares +0.13%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 2.31M USD -90.4%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 20.1M USD -10.9%
Deferred Tax Assets, Valuation Allowance 84.2M USD +12%
Deferred Tax Assets, Gross 97.1M USD +11.9%
Operating Lease, Liability 31.4M USD -4.74%
Depreciation 1.5M USD +15.4%
Payments to Acquire Property, Plant, and Equipment 99K USD -60.4%
Lessee, Operating Lease, Liability, to be Paid 61M USD -7.73%
Property, Plant and Equipment, Gross 26.8M USD +1.66%
Operating Lease, Liability, Current 4.53M USD -9.39%
Lessee, Operating Lease, Liability, to be Paid, Year Two 5.45M USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 5.29M USD +3%
Operating Lease, Weighted Average Discount Rate, Percent 0.14 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 29.6M USD -10.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 5.62M USD +3.01%
Deferred Tax Assets, Operating Loss Carryforwards 53.6M USD +15.1%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 5.78M USD +2.99%
Operating Lease, Payments 1.67M USD -50.2%
Additional Paid in Capital 281M USD +0.82%
Depreciation, Depletion and Amortization 377K USD +18.9%
Share-based Payment Arrangement, Expense 2.33M USD -14.6%
Interest Expense 2.72M USD